In Depth 18 Sep 2024
Two targets, one solution: The rise of bispecific antibodies
Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape looks like.
- Latest Posts
Best in Biotech 17 Sep 2024
Estonia: Seven biotech companies to reckon with
Explore Estonia’s biotech scene with 7 pioneering companies across Tallinn, Tartu, and beyond, fueled by top science parks and universities.
ADCs that deliver: The secret lies in rigorous characterization
Explore the challenges of ADC characterization, key techniques, and the benefits of partnering with a CDMO for effective development.
News and Trends 16 Sep 2024
Vironexis’ AAV vector approach: The next frontier in cancer immunology?
Delve into Vironexis’ launch with a pipeline of 10 cancer drug candidates built around its AAV vectors platform.
Expert Advice 13 Sep 2024
Stealth mode biotech startups: Everything you need to know
Discover all you need to know about stealth mode biotech startups, including what stealth mode is and its advantages and disadvantages.
Podcast 13 Sep 2024
Targeting inflammation: A revolution in disease treatment
NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies. Listen to our conversation with Halia Therapeutics about it.
ADVERTISEMENT
ADVERTISEMENT
In Depth 12 Sep 2024
New treatments being developed for schizophrenia
Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials.
News and Trends 12 Sep 2024
Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges
Delve into the consequences of the Inflation Reduction Act and the broader economic conditions on biotech R&D.
News and Trends 11 Sep 2024
Can Europe revive its biopharma innovation leadership?
Find out if the biotech runner-up, Europe, can step up to boost research and revive its innovation leadership.
News and Trends 10 Sep 2024
Long non-coding RNAs: what’s behind the growing “dark genome” buzz?
Recent deals have zoned in on drugs that target long non-coding RNAs and major moves are currently being made on the R&D front.
Accelerating the path to clinical filing applications with rapid toxicology material delivery
Pre-clinical toxicology studies and prompt material delivery are essential for IND and CTA approvals, crucial for advancing drug candidates to clinical trials.
News and Trends 6 Sep 2024
Psychedelic therapies under scrutiny: What’s next after Lykos’ MDMA rejection?
Delve into the psychedelic-assisted therapy market and investors’ sentiment after the FDA’s decision about Lykos’ therapy.
ADVERTISEMENT